The United Kingdom is set to see the arrival of its first licensed oral weight-loss pill, following the recent approval of the Wegovy pill by the Medicines and Healthcare products Regulatory Agency (MHRA). Manufactured by Danish pharmaceutical firm Novo Nordisk, Wegovy contains semaglutide and offers an alternative to injectable counterparts such as Ozempic and Mounjaro, eliminating the need for needles. The pill is expected to be available in UK pharmacies within weeks, marking a significant milestone in oral obesity treatments.

Novo Nordisk’s approval precedes British-Swedish company AstraZeneca’s development of a similar oral formula, with the latter still in earlier stages. Meanwhile, online retailers have begun inviting potential users to join waiting lists for the new semaglutide pill. Alongside weight reduction, emerging research highlights these medications’ potential to lower risks of heart disease, diabetes, dementia and certain cancers.

Currently, about 1.9 million people in the UK use GLP-1 receptor agonists, the drug class that includes semaglutide. However, the Wegovy pill is not considered the most potent option available. Injectable variants such as Wegovy and Mounjaro remain more effective for weight loss, with additional oral treatments like Eli Lilly’s orforglipron expected to launch in the UK by 2027. Early data suggest orforglipron may produce greater weight reductions and can be taken with or without food, unlike the Wegovy pill, which requires strict fasting conditions.

Access to these medications on the National Health Service (NHS) remains limited. Currently, patients must have a body mass index (BMI) of 40 or more, with four weight-related health conditions, to qualify for free GLP-1 injector treatments. However, eligibility criteria may soon expand to include individuals with a BMI of 35 plus at least one related health issue. Weight-loss pills could become available on the NHS in the future, pending approval from the National Institute for Health and Care Excellence (NICE), although this process may take months or years.

For those seeking to lose between two and four stone outside the NHS framework, private pharmacies offer injectable options such as Wegovy and Mounjaro, costing roughly £100 to £145 per month, respectively. Another investigational drug, reta, targeting three receptors rather than one or two, promises enhanced energy expenditure and fat loss but remains in clinical trials, unlikely to reach the UK before 2027. Concerns about the online purchase of weight-loss medications have increased, with regulators tightening controls to prevent misuse and ensure proper medical supervision.

Individuals hesitant about injections may consider orlistat, an established oral medication that reduces fat absorption. Available both privately and via the NHS under certain conditions, orlistat is less potent than GLP-1 drugs but can facilitate modest weight loss alongside dietary changes. Side effects such as gastrointestinal discomfort may occur if fat intake is not moderated.

For those planning ahead, several next-generation oral obesity treatments are under development from pharmaceutical leaders, incorporating multiple hormone pathways to enhance effectiveness. AstraZeneca is advancing a daily pill known as elecoglipron, showing promising early results, though it is unlikely to be available before 2030.

Cost remains a significant factor in weight-loss drug accessibility. While newer injectables and pills can cost several hundred pounds per month, older drugs like Saxenda, containing the off-patent liraglutide, offer a lower-priced alternative at roughly £95 per month but require daily injections and yield less weight loss.

Premium concierge weight-loss services also offer access to these medications, combined with personalized care and support, albeit at substantially higher fees ranging from £200 to £500 monthly. Alternatively, high-cost residential wellness resorts abroad report successful weight reduction without pharmaceutical intervention.

Common side effects across GLP-1 receptor agonists include nausea, heartburn and digestive disturbances, typically manageable with careful dose escalation and dietary adjustments. Rare but serious complications such as pancreatitis remain uncommon, affecting fewer than 3 percent of patients.

As oral formulations expand options for patients, regulatory developments and ongoing research are likely to shape the future landscape of weight management therapies in the UK.